AI Article Synopsis

  • Tuberculosis (TB) remains a significant global health issue, especially in developing countries, and this study assessed treatment outcomes in South Gondar, Ethiopia, during 2023.
  • A retrospective analysis of 400 TB patients revealed a treatment success rate of 89.0%, which is below the global target of over 90% for 2025, with HIV-positive patients facing higher risks for unsuccessful treatment.
  • Key findings indicated that TB patients who are HIV-positive are nearly three times more likely to have poor treatment outcomes, while patients with sputum-positive TB showed better treatment success rates.

Article Abstract

Background: Tuberculosis is a communicable disease, mainly caused by the bacillus Mycobacterium tuberculosis. Globally, TB is the ninth leading cause of death, with developing countries bearing most of the burden. The discovery of chemotherapy lead to significant improvements in patient survival. Therefore, this study aimed to assess Tuberculosis treatment outcomes and associated factors in South Gondar Administrative Zone Governmental Hospitals, Northwest Ethiopia, 2023.

Method And Materials: A hospital-based retrospective study was conducted from July 1 to August 30, 2022, at South Gondar zone public hospitals. The data was entered into Epi-data version 4 and exported to STATA version 14. A binary and multivariable logistic regression was computed at a 95% confidence interval. Variables with a p-value less than 0.25 in the bivariable analysis were chosen for multivariable logistic regression analysis, and variables having a p-value of less than 0.05 in the multivariable analysis, were considered to have significant associations with the dependent variable.

Results: The study included 400 tuberculosis patients, and the overall successful treatment outcome was 89.0% (95% Confidence Interval: 85.5-91.7). In this study, study participants who tested positive for HIV were approximately three times more likely to have unsuccessful treatment outcomes (Adjusted odds ratio = 3.07; 95% Confidence Interval = 1.49-6.16.5; P = 0.002) relative to HIV-negative patients. On the other hand, patients with sputum-positive were more likely to have a successful treatment rate (Adjusted odds ratio = 0.08; 95% Confidence Interval = 0.011-0.638, P = 0.002) relative to sputum-negative TB patients.

Conclusion: The overall treatment success rate was 89.0%, which was lower than the global milestone target of > 90% set for 2025, and the prevalence of TB-HIV coinfection was 16.5%. In this study, HIV-positive was negatively associated with successful treatment outcomes, and sputum positive was independently associated with successful tuberculosis treatment outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239251PMC
http://dx.doi.org/10.2147/IDR.S413272DOI Listing

Publication Analysis

Top Keywords

tuberculosis treatment
16
treatment outcomes
16
95% confidence
16
confidence interval
16
successful treatment
12
tuberculosis
8
treatment outcome
8
associated factors
8
tuberculosis patients
8
treatment
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!